SCHEMBL22609288

SCHEMBL22609288

Cc1onc(C(=O)O)c1I

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.46
GRIA3 P42263 1/20 0.46
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.41
HCAR2 Q8TDS4 3/20 0.36
TSHR P16473 2/20 0.35
PTPN1 P18031 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
DUSP3 P51452 1/20 0.31
ALDH1A1 P00352 2/20 0.31
GPX4 P36969 1/20 0.31
SMURF2 Q9HAU4 1/20 0.31
SMURF1 Q9HCE7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15248892 0.83 BRD4 (0.41) GRIA1GRIA3LMNARECQLL3MBTL1
SCHEMBL22609347 0.78 NPSR1 (0.45) MEN1KMT2AALDH1A1GPX4
SCHEMBL2131097 0.77 GRIA1 (0.49) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL2807054 0.76 LMNA (0.54) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL13815993 0.74 GRIA1 (0.46) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL5424082 0.74 L3MBTL1 (0.46) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL28206204 0.72 GRIA1 (0.45) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL29187896 0.71 GRIA1 (0.44) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL5451073 0.71 GRIA1 (0.60) GRIA1GRIA3LMNARECQLHCAR2
SCHEMBL28222270 0.70 HCAR2 (0.36) GRIA1GRIA3HCAR2TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS GRIA1 823/4885GRIA3 904/4885LMNA 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.